Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.54 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 4/20 | 0.52 |
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897022 | 0.89 | GRIA1 (0.60) | CES1MAOBGRIA1CACNG8KIF11 | |
| SCHEMBL2362041 | 0.83 | KIF11 (0.58) | CES1MAOBKIF11 | |
| SCHEMBL7376776 | 0.82 | CES1 (0.51) | CES1MAOBGRIA1CACNG8KIF11 | |
| SCHEMBL7126895 | 0.81 | MAOB (0.50) | MAOBGRIA1CACNG8GAA | |
| SCHEMBL25899778 | 0.81 | MAOB (0.55) | MAOBGRIA1CACNG8KIF11AHR | |
| SCHEMBL7348899 | 0.80 | MAOB (0.61) | MAOBGRIA1CACNG8KIF11AHR | |
| SCHEMBL7126943 | 0.79 | KIF11 (0.46) | MAOBGRIA1CACNG8KIF11GAA | |
| SCHEMBL20214 | 0.78 | PDE3B (0.66) | MAOBGRIA1CACNG8AHREIF2AK2 | |
| SCHEMBL31040124 | 0.78 | PDE3B (0.66) | MAOBGRIA1CACNG8AHREIF2AK2 | |
| SCHEMBL3310995 | 0.78 | KIF11 (0.70) | CES1MAOBGRIA1CACNG8KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206857-B | Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions comprising the same | 韩国生命工学研究院 | 2024-09-06 | — | — | CN | disclosed |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| WO-2023104170-A1 | COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104170-A1 | COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2023-06-15 | — | — | WO | disclosed |
| EP-4186503-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | Korea Research Institute of Bioscience and Biotechnology (KR) | 2023-05-31 | — | — | EP | disclosed |
| CN-116157120-A | Anti-inflammatory compositions comprising benzofuranyl N-acylhydrazone derivatives | 韩国生命工学研究院 | 2023-05-23 | — | — | CN | disclosed |
| EP-4015516-A1 | BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2022-06-22 | — | — | EP | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| CN-101970426-A | Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIV HEALTH NETWORK | 2011-02-09 | — | — | CN | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | JIANGSU SIMCERE PHARMACEUTICAL R&D CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-2123649-A1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
| CN-101389624-A | 3-pyrrolocyclohexylidene-2-indolinone derivative and application thereof | JIANGSU SIMCERE PHARMACEUTICAL (CN) | 2009-03-18 | — | — | CN | disclosed |
| US-20020091107-A1 | Oxazolidinone antibacterial agents | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002020515-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | PTK2B, DMPK, STK25 | CES1 2599/4885MAOB 1059/4885GRIA1 3840/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | CES1 4080/4885MAOB 2404/4885GRIA1 2846/4885 |
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | CES1 4336/4885MAOB 1759/4885GRIA1 103/4885 |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | RELA, NFKBIA, IKBKG | CES1 4013/4885MAOB 3098/4885GRIA1 2569/4885 |
| US-20020091107-A1 | Oxazolidinone antibacterial agents | OXA1L, TOP1, MT-ND1 | CES1 2297/4885MAOB 1518/4885GRIA1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.